TSH Biopharm Corporation Limited (TPEX:8432)

Revenue by Segment

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Cardiovascular and Gastrointestinal Drugs Business Group	656.95M	628.51M	497.31M	647.38M	413.48M
Cardiovascular and Gastrointestinal Drugs Business Group Growth	4.52%	26.38%	-23.18%	56.57%	-7.68%
Reinvestment Business Group	765.97M	551.28M	313.61M	93.69M	-
Reinvestment Business Group Growth	38.94%	75.78%	234.74%	-	-
Adjustment and Elimination	-86.40M	-64.07M	-	-	-
Total	1.34B	1.12B	810.92M	741.07M	413.48M
Total Growth	19.79%	37.59%	9.43%	79.23%	-7.68%

Revenue by Geography

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Taiwan	1.34B	1.12B	810.92M	741.07M	413.48M
Taiwan Growth	19.79%	37.59%	9.43%	79.23%	-7.68%
Total	1.34B	1.12B	810.92M	741.07M	413.48M
Total Growth	19.79%	37.59%	9.43%	79.23%	-7.68%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 19, 2026

Data Sources Report a data error